Zobrazeno 1 - 10
of 367
pro vyhledávání: '"B Verstockt ."'
Publikováno v:
Frontiers in Gastroenterology, Vol 2 (2023)
In the current treat-to-target era, close and tight monitoring of patients with inflammatory bowel disease has become increasingly important. Although the importance of patient reported outcomes (PROMs) cannot be underestimated, its moderate associat
Externí odkaz:
https://doaj.org/article/a0916982223b4a9fac438fe384562123
Publikováno v:
Acta Gastro Enterologica Belgica. 86:98-101
Crohn’s disease (CD) is a chronic inflammatory bowel disease often presenting with extraintestinal manifestations. However, pulmonary involvement in CD is quite rare. We here report a case of CD with pulmonary manifestation as the first presenting
Publikováno v:
Journal of Crohn's and Colitis. 17:i501-i505
Background Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) were recently approved for maintenance treatment of patients with inflammatory bowel disease. However, further investigation is required to identify the patients most
Autor:
C O'Neill, S Haenen, W Coudyzer, G Bislenghi, A D'Hoore, B Verstockt, M Ferrante, S Vermeire, J Sabino
Publikováno v:
Journal of Crohn's and Colitis. 17:i319-i321
Background Sarcopenia (loss of skeletal muscle mass and/or strength) is a predictor of postoperative morbidity in various surgical populations. We evaluated the impact of sarcopenia in postoperative outcomes after intestinal surgery in patients with
Autor:
E Melón-Ardanaz, M Veny, A M Corraliza, A Garrido-Trigo, M Esteller, M Rodrigo, B Verstockt, S Vermeire, M C Masamunt, Á Giner, I Ordás, A Fernández-Clotet, E Ricart, J Panés, A Salas
Publikováno v:
Journal of Crohn's and Colitis. 17:i62-i64
Background Tofacitinib is an oral JAK1 and JAK3 inhibitor approved for the treatment of moderate to severe ulcerative colitis (UC). The aim of this study is to identify the relevant cellular subsets and genes involved in response and/or resistance to
Publikováno v:
Journal of Crohn's and Colitis. 17:i146-i148
Background Molecular biomarkers are emerging as promising tools to predict response to advanced therapy in IBD. For instance, mucosal expression of Triggering Receptor Expressed on Myeloid cells-1 (TREM1) and oncostatin M (OSM) are associated with an
Autor:
D Bettenworth, M E Baker, W Bemelmann, D Bruining, G D’Haens, A D’Hoore, A Dignass, I Dotan, B G Feagan, R Feakins, P Fleshner, J G Fletcher, I Gordon, C Ha, H Gaylyn, V Jairath, C Lu, R Lyu, S C Ng, J Panes, G Rogler, R Mao, J Rimola, W J Sandborn, B Siegmund, M S Silverberg, S Taylor, B Verstockt, F Rieder
Publikováno v:
Journal of Crohn's and Colitis. 17:i418-i420
Background Small bowel fibrostenotic strictures are common in patients with Crohn’s disease (CD). No global consensus recommendations on definitions, diagnosis and clinical management are available. Methods Several systematic reviews followed by a
Publikováno v:
Journal of Crohn's and Colitis. 17:i797-i799
Background There is an ongoing debate whether the type of anastomosis following intestinal resection for Crohn’s disease (CD) can have an impact on complications and postoperative recurrence. The aim of the present study is to describe the outcome
Publikováno v:
Journal of Crohn's and Colitis. 17:i67-i69
Background Eosinophils might play a pro-inflammatory role in inflammatory bowel disease (IBD). However, the role of eosinophils in intestinal fibrosis remains poorly understood, although a pro-fibrotic function has been hypothesized based on data out
Autor:
S Verstockt, K Machiels, J Dehairs, K Rems, I De Greef, D Jans, J Sabino, M Ferrante, S Vermeire, B Verstockt
Publikováno v:
Journal of Crohn's and Colitis. 17:i1-i3
Background An ileocolonic resection with ileocolonic anastomosis is often required in patients with Crohn’s disease (CD). Postoperative recurrence (POR) is common, with host-luminal interactions being implicated. However, these interactions are poo